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Background: Alveoli, the milk-producing units of the mammary gland, are generated during pregnancy by
collaboration of different epithelial cell types. We present the first analysis of transcriptional changes within the hormone
sensing population during pregnancy. Hormone-receptor positive (HR+) cells play a key role in the initiation of
alveologenesis as they sense systemic hormonal changes and translate these into local instructions for neighboring
HR- cells. We recently showed that IGF2 is produced specifically by HR+ cells in early pregnancy, but is undetectable in
the virgin state. Here, we define the transcriptome of HR+ cells in early pregnancy with the aim to elucidate
additional changes that are unique for this dynamic developmental time window.
Results: We harvested mammary glands from virgin, 3-day and 7-day pregnant mice and isolated a few hundred
hormone-sensing cells per animal by FACS for microarray analysis. There was a high concordance between animals
with a clear induction of cell cycle progression genes at day 3 of pregnancy and molecules involved in paracrine
signalling at day 7.
Conclusions: These findings underscore the proliferative capacity of HR+ cells upon specific stimuli and elucidate
developmentally-restricted changes in cellular communication. Since the majority of breast cancers are HR+, with
a variable proportion of HR+ cells per tumor, we anticipate that this data set will aid further studies into the regulation
of HR+ cell proliferation and the role of heterotypic signalling within tumors.
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The adult mammary gland of the mouse contains a
branching structure of epithelial milk ducts embedded
in the mammary fat pad. The epithelial ducts are bi-
layered; the outer basal layer consists mainly of contract-
ile myoepithelial cells and the luminal layer contains
both hormone receptor positive (HR+) and negative
(HR-) cells. HR+ cells are identified by their expression
of the steroid hormone receptors for estrogen and pro-
gesterone (ER and PR) [1], and they also have a high ex-
pression of the prolactin receptor [2]. Luminal HR- cells
are characterised by expression of the transcription* Correspondence: apietersen@gmail.com
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unless otherwise stated.factor Elf5 and already express low levels of milk genes
even in the virgin state [2,3]. In the adult virgin epithelial
cells rarely proliferate, but the ones that do are usually
luminal HR- cells [4,5]. In in vitro assays, HR- cells form
colonies whereas the majority of HR+ cells are non-
clonogenic [6]. Together, this has led to the concept that
HR+ cells are relatively mature, or terminally differenti-
ated, cells [7,8]. However, Ewan and colleagues showed
that TGFbeta signaling is actively required to prevent
proliferation by HR+ cells [9] and another report docu-
mented a 10-fold increase in proliferating HR+ cells
in early pregnancy [10]. Interestingly, a study that used
ovarectomized mice treated with hormone injections to
mimic early pregnancy in a time-controlled manner
showed that there is a short first wave of proliferation of
HR+ cells, followed by a larger wave of proliferation of
HR- cells [11].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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milk ducts on which lobular structures of alveoli (future
sites of milk production) are formed [1]. HR- luminal
cells are molecularly primed for milk production and as
such are referred to as alveolar progenitor cells. How-
ever, these progenitor cells do not provide all the pro-
geny that generate the alveoli. Recent data by others and
us showed that alveologenesis occurs to a large extent by
collaborative outgrowth of the three main epithelial cell
lineages; basal cells and luminal HR+ and HR- cells
[12-14]. This is consistent with an important role for
cellular communication in alveolar development [15].
Pregnancy causes an increase in progesterone and pro-
lactin levels and both these hormones are required for
the initiation of alveologenesis [1]. HR+ cells translate
these systemic hormonal signals into local instructions
for neighboring cells by paracrine signaling. For instance,
progesterone and prolactin induce expression of RANKL
[2,16], a growth factor that is essential to induce proli-
feration of neighboring HR- cells [11]. In addition, we
found that another growth factor that is essential for
alveologenesis, IGF2 [17], was produced specifically by
HR+ in early pregnancy [2]. Notably, IGF2 is undetect-
able in virgin state [2] and therefore we wondered what
other factors these cells produce specifically during ac-
tive morphogenesis in early pregnancy.
Here, we analyzed the transcriptome of HR+ cells at
two early time points in naturally-induced pregnancy to
characterize these cells in a state of active proliferation
and cellular communication.
Results and discussion
Pregnancy induces proliferation in both HR+ and
HR- cells
To characterize the changes that occur in HR+ cells in
early pregnancy, we obtained mammary glands from FVB/
N mice that were adult virgins (nulliparous), and from
timed-mated mice at day 3 and day 7 of pregnancy.
Carmine staining of the thoracic mammary glands con-
firmed the presence of relatively bare milk ducts at the vir-
gin state (metestrus), increased branching and thickening
of the ducts at day 3 of pregnancy and the appearance of
alveolar structures by day 7 of pregnancy (Figure 1A). We
evaluated the proliferative status of the HR+ cells by EdU
injection 24 hours before harvest. Paraffin sections were
stained with antibodies against cytokeratin 8 (CK8, blue)
to identify luminal epithelial cells and the estrogen recep-
tor (ER, red) as a marker for HR+ cells. In this case, we
chose ER to identify HR+ cells but it is important to note
that not all ER+ cells co-express the progesterone receptor
(PR) and vice versa [5]. This can be due to receptor down-
regulation upon active signaling [18] but potentially could
also indicate a further heterogeneity within the HR+ cell
population [19]. Similar to previous literature [4,10], wefound that in mammary epithelium not many epithelial
cells are proliferating in the virgin state, and the rare cells
that do are all ER- (Figure 1B). Pregnancy induced consid-
erable proliferation of luminal epithelial cells, including
the ER+ cells (Figure 1B and C). By day 7 of pregnancy,
the proportion of proliferating luminal cells that are ER+
diminishes, whereas the proportion of proliferating ER-
luminal cells (that are primed for milk production)
continues to increase (Figure 1C). Beleut and colleagues
demonstrated that steroid hormone injections first in-
duced proliferation in a portion of progesterone receptor
positive (PR+) cells, followed by proliferation in a much
larger proportion of PR- cells [11]. Our data show that this
response also occurs during a natural pregnancy, in which
ER +HR+ cells proliferate for a brief initial period,
whereas the luminal HR- cells also start proliferating early
on, but continue to expand considerably during the course
of pregnancy.
Identification of HR+ cells by cell surface markers in early
pregnancy
To identify molecular changes during the burst of prolifer-
ation of HR+ cells, we isolated HR+ epithelial cells from
the abdominal mammary glands of virgin mice at metes-
trus and 3-day and 7-day pregnant mice. Single cells were
stained with cell surface markers and isolated by FACS.
After exclusion of doublets, dead cells and lymphocytes,
luminal epithelial cells were identified by their high expres-
sion of CD24 and relatively low expression of alpha6-
integrin (CD49f, see gating strategy in Additional file 1 and
2). The luminal cell population was separated into HR+
and HR- cells based on Sca1 (Ly6A) and alpha2-integrin
(CD49b) expression (Figure 2A). The proportions of the
various FACS populations for individual animals can be
found in Additional file 2. Notably, Sca1 expression went
gradually down in HR+ cells upon pregnancy. Due to the
continued proliferation of the luminal HR- cells, the rela-
tive proportion of HR+ cells at day 7 of pregnancy is con-
siderably smaller compared to the virgin state (Figure 2A).
To ensure that the cell surface profiles in pregnancy still
identified the HR+ population despite the changes in Sca1
expression, the two distinct populations were sorted for
qPCR analysis. We made use of a direct lysis method we
recently developed for mRNA analysis of small numbers of
cells [20] and 500 cells per population were analyzed from
three individual mice. There is some fluctuation in hor-
mone receptor transcription during pregnancy (Figure 2B),
which could be due to changes in transcriptional activity
but also potentially to alterations in cellular subsets within
the HR+ population [19]. Note that ER protein levels
go down in early pregnancy (Additional file 3) but ER
transcript levels do not. Because ligand binding induces
hormone receptor degradation [18] the relation between
transcript and protein levels is not straight forward.
Figure 1 Pregnancy induces proliferation in both the HR+ and HR- cells. (A) Representative images of carmine-alum-stained whole mounts
of mammary glands from virgin, 3-day and 7-day pregnant FVB/N mice. Scale bar, 1 mm. (B) Confocal immunofluorescence of mammary gland
sections from virgin, 3-day and 7-day pregnant mice stained for the proliferation marker 5-ethynyl-2’-deoxyuridine (EdU, green), Estrogen Receptor
(ER, red) and the luminal cell marker cytokeratin-8 (CK8, blue). Scale bar, 10 μm. The exposure time for the ER signal was increased in pregnant
samples to allow robust identification of ER+ cells (see Additional file 3 for images with a fixed exposure time). (C) Quantification of the proportion of
luminal cells that is proliferating, separated by cell type based on ER expression. ER+ and ER- luminal cells start proliferating at day 3 of pregnancy, by
day 7 the majority of proliferating luminal cells are ER-. Bars represent individual animals.
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population clearly contains the HR+ cell population des-
pite the reduction in Sca1 expression. In addition, the HR-
population is identified by the expression of Elf5 and this
population does not contaminate the HR+ population
sorted based on Sca1 and CD49b (Figure 2B).Transcriptome analysis of HR+ cells obtained in early
pregnancy
To carry out a comprehensive gene expression analysis of
the changes that occur in HR+ cells in early pregnancy,
we adapted our direct lysis protocol for microarray ana-
lysis. In this case, we sorted a thousand HR+ cells per
Figure 2 Purification of HR+ cells by FACS in early pregnancy. (A) The luminal population of mammary epithelial cells (CD24hiCD49flo) was
separated into hormone-sensing cells (Sca1hi CD49blo; purple gate) and alveolar progenitor cells (Sca1lo CD49bhi; orange gate). (B) Quantitative
RT-PCR on 500 directly-lysed cells per sample for markers that distinguish the two luminal cell types. Values are relative to mRNA levels in HR+
cells from virgin animals and normalised to HPRT expression. Error bars indicate standard deviation for 3 individual mice.
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amplification and subsequent hybridization to Illumina ar-
rays. Note that this cell number is low enough to allow
sampling from individual mice even when the cellular sub-
set is small, while the cell number is large enough to pro-
vide a robust average of the population without the need
for many repeats, as would for instance be the case with
single cell analysis. The assumption that a few hundred
cells per population provides a consistent representation of
the changes that occur within the HR+ cell population is
supported by the high reproducibility of the transcriptional
profiles of samples taken from individual animals (n = 3 an-
imals per time point), as indicated by a principal compo-
nent analysis (Figure 3A). Unsupervised hierarchical
clustering also confirms that the HR+ populations of the
different time points are most similar to samples of the
same developmental stage (Figure 3B).At day 3 of pregnancy, there is a set of 165 genes that
have changed more than 2 fold compared to the virgin
samples and that are distinct from changes that occur at
day 7 of pregnancy. There is a larger group of 401 genes
that is changed at both the 3-day and 7-day time point,
in addition to 605 genes whose expression only starts
changing at day 7 of pregnancy (Figure 3C, genes listed
in Additional file 4).
Figure 4A illustrates that distinct gene clusters can be
recognized based on the direction of the transcriptional
changes. For instance, there are genes that are strongly
upregulated at day 3 but are reduced again at day 7
(Figure 3B), genes that are induced gradually from day
3 to day 7 (Figure 3C), or become induced only by day
7 (Figure 3D). Similar trends can be observed for
downregulation of genes, in which a cluster of genes is
abruptly downregulated at day 3 (Figure 3E), but there
Figure 3 Transcriptome analysis clusters HR+ cells by developmental state. (A) Principal Component Analysis (PCA) was performed on
three biological replicates of HR+ cells derived from virgin (Vir), 3-day (3D) and 7-day (7D) pregnant mice based on 19,821 probes (see Methods
for details). A scatterplot of the first two principal components demonstrates a separation by pregnancy along the first principal component (PC1)
and by duration of pregnancy along the second principal component (PC2). (B) Unsupervised hierarchical clustering based on 1328 probes
(probes with an absolute fold-change > =2 and false discovery rate (FDR) of 10% or less) shows that the biological replicates cluster according to
developmental state. (C) Venn diagram illustrating the number of genes that were changed more than 2-fold with a FDR of 10 in the 3 replicates
of HR+ cells isolated at day 3 of pregnancy (3D, light grey) compared to virgin samples and the overlap of this gene set compared to differentially
expressed genes at day 7 of pregnancy (7D, dark grey, more than 2 fold change compared to virgin).
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the progression of pregnancy (Figure 3F) and some genes
are only downregulated by day 7 (Figure 3G).
Response of HR+ cells at day 3 of pregnancy is
characterized by proliferation and changes in hereditary
breast cancer pathways
In our previous work, we noticed that IGF2 transcription
is strongly induced in HR+ cells in early pregnancy [2].
Analysis of the microarray data shows that additional
players in the IGF signalling network are also induced
(Figure 5A), such as Insulin-like growth factor acid labile
subunit (IGFALS) which increases the half-life of IGFs
[21] and also two Insulin-like growth factor binding pro-
teins (IGFBP5 and IGFBP7) that have opposing roles in
mammary gland involution [22,23]. The long non-coding
RNA H19, whose transcription is tightly linked to that of
IGF2 [24], is strongly induced already at day 3 of preg-
nancy (Figure 5A). This seems earlier than the induction
of IGF2, but that could also be due to differences in detec-
tion sensitivity of the array. Both IGFBP5 and H19 have
been suggested to antagonise IGF signalling and therefore
these data suggest an intricate regulation of IGF signalling
in mammary epithelium in early pregnancy.
An unbiased examination of changes in signalling
pathways was performed by Ingenuity Pathway analysis.
The pathways that were most significantly changed in
HR+ cells at day 3 of pregnancy compared to the virgin
samples comprised pathways related to the cell cycle
and DNA repair check points (Figure 5B). Interestingly,
several of the transcriptional changes at day 3 occur ingenes that have been implicated in hereditary breast can-
cer, such as p53, Chek2 and FANCD2. A complete list of
the 27 genes that are responsible for the significant change
in the Hereditary Breast Cancer Ingenuity Pathway is in-
cluded in Additional file 5. At day 7 of pregnancy, changes
grouped according to Ingenuity signalling pathways were
less significant and occurred to some extent already at day
3 (Figure 5B). These pathways were mostly related to im-
mune function and cell migration and included genes such
as integrins and PI3KR3, that were for instance assigned
to the Ingenuity pathway ‘invasive glioma signaling’.
The individual genes whose transcription is changed
most dramatically in HR+ cells in early pregnancy are
listed in Figure 6. For instance, at day 3 of pregnancy
several of the most highly induced genes are involved in
proliferation (Figure 6A). This includes cell cycle genes
(CDCa3 and CDCa8) and mitotic genes such as PDZ-
binding kinase (PBK) [25], Kinesin-like protein 22 (Kif22),
Kinetochore associated 1 (KNTC1), Nucleolar and spindle-
associated protein 1 (Nusap1). Minichromosome mainten-
ance complex component 5 (MCM5) is a DNA replication
licensing factor [26] and RAD54B plays a role in hom-
ologous recombination and repair of DNA [27]. Additional
file 6 contains a summary of genes involved in the cell
cycle that are transcriptionally changed in early pregnancy.
Other top upregulated genes at day 3 of pregnancy are
known targets of steroid hormones, such as calcitonin
(CALCA) and IGFALS [28,29]. The genes that are strongly
down regulated at pregnancy day 3 are mostly similar to
the genes that are down regulated at day 7 (Figure 6B) and
they do not cluster into obvious functional groups.
Figure 4 Heat maps of transcriptional changes in HR+ during early pregnancy. (A) Heat map of Illumina gene probes generated by
GenePattern software showing transcriptional changes during early pregnancy. (B-C) Heat maps generated with an input of the 25 most up-regulated
and 25 most down-regulated genes in each category based on the values of their Pi scores (see Methods). Twenty-five gene probe sets that are
induced (B) and reduced (C) most strongly in HR+ cells specifically at day 3 of pregnancy. (D-E) Gene probe sets that are most strongly induced
(D) and reduced (E) in early pregnancy. (F-G) Gene probe sets that are induced (F) and reduced (G)most strongly in HR+ cells specifically at day 7
of pregnancy.
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tabolizes trypthophan, has a potentially immunosuppres-
sive role and high IDO expression in ER+ breast cancer is
associated with a better overall survival [30,31]. D site of
albumin promoter (albumin D-box) binding protein (DBP)
is a transcription factor that for instance binds to the insu-
lin promoter. The sodium/iodide transporter (SLC5A5) is
negatively regulated by IGF-1 and TGF-beta signalling in
the mammary gland [32] and therefore its down regulation
may be a reflection of increased IGF signalling.
Taken together, at day 3 of pregnancy the most striking
change in the transcriptome of HR+ cells compared to HR
+ in the non-pregnant mammary gland is the induction of
proliferation. This is indicated by the Ingenuity PathwayAnalysis, the individual genes that change most signifi-
cantly based on the microarray analysis, and this was fur-
ther validated by qPCR on some of the cell cycle genes on
independent cDNA samples (Figure 7A).
Transcriptional changes in HR+ cells at day 7 of
pregnancy involve immune regulation and cellular
communication
The expression of cell cycle progression genes is still ap-
parent at day 7 of pregnancy, but to a lesser extent. This
is consistent with the initial wave of proliferation in HR
+ cells that is superseded by proliferation in the luminal
HR- cells (Figure 1). Part of the overlap in gene changes
at pregnancy day 3 and day 7 (Figure 3C) is due to the
Figure 5 Pathway analysis of changes in HR+ cells during early pregnancy. (A) Bar chart of the transcriptional changes of genes involved in
IGF signaling. Values are normalized Log2 values of Illumina probe sets, error bars denote standard deviation of three biological replicates. The
dotted red line indicates background noise. (B) Ingenuity Pathway Analysis showing canonical pathways that are most significantly changed at
day 3 of pregnancy (blue) and at day 7 of pregnancy (green) compared to virgin samples. The number of genes in each pathway that was
significantly changed in the HR+ samples is indicated at the top of each bar.
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cesses that partially overlap that are only just detectable
at day 3 and become much more robust at day 7. For in-
stance, the induction of progesterone targets calcitonin
and RANKL is detectable at day 3 of pregnancy, but the
fold induction is much higher at day 7 (Figure 7B). An-
other target of the progesterone receptor (PR), Wnt4, is
not detectable with the relatively low sensitivity of the
microarray but an increase in Wnt4 expression at day 7
of pregnancy can be detected by qPCR (Figure 7B). Cyc-
lin D1 has also been found to be partially regulated by
PR [33] but we do not find evidence for Cyclin D1
induction either by microarray or qPCR (Figure 7B).
Induction of cyclin D1 transcription was described
24 hours after progesterone injection, but in that case
RNA from the entire mammary gland was used [34], im-
plying that the cyclin D1 induction could have occurred
in neighboring HR- cells.
In addition to elevated cell cycle genes and known
hormone-induced target genes, this data set provides
insight to other processes that are initiated in HR+ cells
at day 7 of a murine pregnancy, the time when alveoli
become clearly visible (Figure 1A). In Figure 7, we high-
light a few of the top molecules that are all secreted fac-
tors (with the exception of Cyclin D1). A complete listof transcriptional changes in secreted factors (annotation
by Ingenuity) is included in Additional file 7.
WFDC (WAP four-disulfide core domain) is a prote-
ase inhibitor with a potential role in immune regulation.
Interestingly, WFDC is part of the same gene cluster as
SLPI (Secretory Leukocyte Protease Inhibitor) [35] and
both genes are strongly induced in HR+ cells at preg-
nancy day 7 (Figure 4C, 6B and 7C). Secreted SLPI spe-
cifically reduces growth of mammary but not colon
cancer cells grown in mice [36], suggesting a functional
role for SLPI in mammary epithelial cells. The role of
the induced SFTPD (Surfactant, pulmonary-associated
protein D) seems straight forward; surfactant secretion
prevents the collapse of lung alveoli and likely also of
the developing mammary alveoli that become apparent
by day 7 of pregnancy. In addition, SFTPD is thought to
play an important role in innate immunity because it
binds a wide variety of microorganisms and may modulate
leukocyte responses [37]. Curiously, DMBT1 (Deleted in
Malignant Brain Tumors 1) is also expressed in the lung
and seems to interact with SFTPD at the protein level
[38]. DMBT1 is induced in inflammatory conditions as
part of an anti-microbal defense but it is downregulated
in the process of terminal differentiation in gastric epi-
thelia [39]. Our data show that DMBT1 is strongly
Figure 6 Top molecules that are differentially expressed in HR+ cells in early pregnancy. (A) Molecules identified by Ingenuity Pathway
Analysis that are most strongly down- and upregulated in HR+ cells at day 3 of pregnancy compared to virgin samples. (B) Molecules identified
by Ingenuity Pathway Analysis that are most strongly down- and upregulated in HR+ cells at day 7 of pregnancy compared to virgin samples.
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In contrast, SFTPD is strongly induced and it is currently
unclear whether in mammary alveologenesis DMBT1 and
SFTPD are functionally linked. Similar to its downregu-
lation in early pregnancy, DMBT1 expression is also
reduced in breast cancer where its expression was anti-
correlated with the proliferation marker MCM5 [40].
Thus, the downregulation of DMBT1 in HR+ cells in early
pregnancy could be related to an induction of prolifera-
tion. Taken together, several of the most strongly induced
genes play a role in the protection against microorganisms.
Speculatively, there may be an increased risk for a com-
promised epithelial barrier during active morphogenesis.
Another category of induced genes is involved in cell
to cell communication. IGF2 is a prime example of this
(Figure 7D), but we also observed the induction of for
instance Midkine (MDK) and IL-19 and a strong down-
regulation of IL-33 (Figure 7D). Like IGF2, Midkine is a
growth factor (MDK is also known as neurite growth
promoting factor 2) and is widely expressed during em-
bryogenesis but is absent from most adult tissues with
the notable exception of the nervous system [41]. We
show here that it is just detectable in virgin HR+ cells(average Ct of 33) and strongly induced in pregnancy
(average Ct of 28 at day 7, Figure 7C). MDK has been
reported to promote proliferation of cancer cells [42].
However, reports about its role in breast cancer are
contradictory [43-45] and warrant further investigation
of the role of MDK in the different mammary epithelial
cell types in normal and malignant mammary deve-
lopment. The cytokine IL-19 was approximately 8-fold
upregulated in the biological replicates used for the
microarray analysis, but the independent validation by
qPCR showed a more moderate response (Figure 7D). It
will nevertheless be interesting to further explore the
role of IL-19 because it induces proliferation and migra-
tion of breast cancer cells and the expression of IL-19 is
correlated with a poor clinical outcome [46]. IL-33 is
highly expressed in epithelial barrier tissues [47] and
thought to act as an ‘alarmin’ that amplifies the innate
immune response in case of tissue damage [48]. In con-
trast to the other genes shown in Figure 7D, IL-33 is
abruptly downregulated, possibly to prevent an ‘alarmist’
response in case of alveolar morphogenesis. Preliminary
data suggest that IL-33 enhances tumor growth in
a mouse model of breast cancer [49] and it will be
Figure 7 Quantitative polymerase chain reaction (qPCR) validation of the transcriptional changes in HR+ in early pregnancy. (A)
Relative mRNA expression of cell cycle genes during pregnancy compared to virgin samples, normalised to HPRT expression. (B) Relative mRNA
expression of progesterone target genes during pregnancy compared to virgin samples, normalised to HPRT expression. (C) Relative mRNA
expression of secreted factors during pregnancy compared to virgin samples, normalised to HPRT expression. N.D.: Not Detected. Error bars
indicate standard deviation for 3 individual mice.
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IL-33 in the mammary gland.
Conclusion
Pregnancy induces considerable changes in the mammary
gland, and many studies have characterized this. Molecu-
lar analysis has been primarily performed on entire mam-
mary glands, thereby blending the characteristics of all cell
types of the fat pad and all epithelial cells types [50,51].Sorting mammary epithelial cell populations based on cell
surface markers has already provided new insights into
cell-type specific transcriptomes of the three epithelial lin-
eages in the adult virgin gland [3,8] and of the involuted
mammary gland [52]. Here, we have taken that a step fur-
ther and analyzed the dynamic transcriptional changes
within a specific cell population in early pregnancy. We
focussed on the changes in HR+ cells specifically, but
similar dynamic changes are likely to occur in the other
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underscore that HR+ proliferate as part of a normal de-
velopmental program that is active in early pregnancy.
Estrogen-dependent proliferation is one of the defining
features for ER+ breast cancer, however this has been
considered a newly acquired trait because ER+ cells in
normal non-pregnant breast tissue rarely proliferate. It
will be interesting to explore to what extend ER+ cancer
cells hijack this developmentally-restricted program.
The transcriptional changes at day 7 of pregnancy show
a wide range of responses, part of which seem to involve
the increase in anti-microbial defense which might be due
to a suboptimal barrier function during active epithelial
morphogenesis. Another part of the response at day 7 is
likely involved in the coordination of the collaborative out-
growth of different epithelial cell types to form the milk-
producing alveoli. Many of the most significantly changed
genes have a role in breast cancer and given the hetero-
geneity within breast tumors, where ER+ breast tumors
can contain as few as 10% ER+ cells [53], it will be import-
ant to investigate heterotypic signaling in both normal and
malignant mammary gland development.Methods
Mice and timed mating
All experiments were conducted with FVB/N mice pur-
chased from Jackson Laboratory and bred and maintained
in the animal facility of the DUKE-NUS Graduate Medical
School and The National Cancer Centre, Singapore. All
animal protocols were approved by the SingHealth Insti-
tute Animal Care and Use Committee. The virgin controls
were injected with EdU at metestrus when 11 weeks old
and mammary glands were harvested 24 hours later. For
the early-pregnancy time-points, mice were timed-mated
when 9-11 weeks old. Female mice at estrus were placed
in the cage of a male after 10 pm and checked for vaginal
plugs at 8 am the following morning (Day 0). Mice were
injected with EdU 24 hours before euthanizing 3 days or
7 days later by carbon dioxide inhalation. 2 mg/g body
weight of EdU (Molecular Probes #C10337) was injected.Carmine staining of whole-mounted mammary glands
A #3 (thoracic) gland was fixed in methacarn (60%
methanol, 30% chloroform, 10% acetic acid) between
glass slides for 24 hours. Subsequently the gland was
placed in 70% ethanol for 24 hours, then immersed in
0.2% carmine (Sigma #C1022)- 0.5% aluminum potas-
sium sulfate (Aldrich) stain for 18 hours. Next, glands
were transferred to 70%, 90% and 100% ethanol for
1 hour each, followed by 100% ethanol for 18 hours.
Finally glands were transferred to methyl salicylate
(Sigma #M2047) for visualisation and photography with
an Olympus SZX12 microscope.Confocal immunofluorescence
Fresh #3 (thoracic) glands were fixed for 18 hours in
4% buffered formaldehyde (ICM Pharma), processed and
embedded in paraffin wax. 5 μm sections were cut and ad-
hered to Superfrost Plus coated slides (Menzel-Glaser
#J1800AMNZ) overnight at 37°C. Sections were de-
paraffinized in Xylene (2× 5 minutes) and hydrated by
sequential incubation in ethanol solutions of decreasing
concentration (100% ethanol 2× 5 minutes, 90% ethanol 2×
5 minutes, 70% ethanol 2× 5 minutes and distilled H2O
5 minutes). Antigen retrieval was performed in 600 mL of
1 mM disodium-EDTA by heating in a microwave on high
for 5 minutes and on 30% power for an additional 5 minutes
and then cooled at room temperature for 1 hour. Slides
were immersed in distilled H2O and washed in PBS for
5 minutes. Sections were encircled with a wax pen and in-
cubated for 30 minutes at room temperature with the
Click-iT reaction mix (Molecular Probes #C10337),
prepared as described by the manufacturer. Primary anti-
body was diluted in PBS (for dilutions and suppliers, see
Additional file 8) with 10% normal serum from the species
in which the secondary antibody was raised, was applied
and incubated at 4°C overnight. Sections were washed in
PBS (3× 5 minutes) before the addition of secondary anti-
body (in PBS + 10% normal serum), for 30 minutes at room
temperature. Sections were washed in PBS (2× 5 minutes)
and stained with DAPI (1 μg/mL) for 2 minutes at room
temperature. Sections were then washed in PBS and
mounted in Vectashield fluorescence mounting media
(Vector Laboratories #H-1000). Images were acquired on a
Zeiss 710 confocal microscope with a pinhole aperture of 1
airy unit. For cell enumeration, at least 20 fields were ran-
domly selected and greater than 1300 luminal cells counted
per animal. Of note, ER protein levels decrease upon preg-
nancy (see Additional file 3) and to allow accurate identifi-
cation of ER+ cells for quantification we increased the
exposure of samples derived from pregnant animals to a
signal that was similar to the samples derived from virgin
mice (Figure 1).
Isolation of primary mammary epithelial cells
Mammary epithelial cells (MECs) were isolated according
to [54], with minor modifications [2]. The #4 and #5 mam-
mary glands were excised after removal of mammary lymph
nodes and were mechanically and enzymatically digested to
single cells. The glands from one animal were pooled and
processed as one sample. For more details, see [2]. Single
cells were resuspended in L15 medium with 6% FCS,
counted and kept on ice during antibody staining for FACS.
Cell labeling, flow cytometric analysis & fluorescence-
activated cell sorting (FACS)
Fluorochrome-conjugated antibodies were titrated on
primary mammary epithelial cells to ensure maximal
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Anti-mouse &/or anti-rat compensation beads (BD
#552843 and #552845, respectively) were used for single
stain antibody controls. Compensation controls also in-
cluded two cellular samples: unstained cells and cells with
DAPI (Sigma #D8417). Single cell samples from individual
animals (3 animals per time point) were incubated with
antibodies on ice for 45 minutes with agitation each 15 mi-
nutes. Samples were then washed with twice the sample
volume and resuspended in L15+ containing 200 ng/mL
of DAPI, except non-DAPI compensation controls. All
multiple-labelled samples were gated on FSC-A vs. SSC-A
and doublet discrimination (FSC-H vs. FSC-W & SSC-H vs.
SSC-W) and DAPI negativity (Additional file 1). Samples
contained anti-CD45 to exclude lymphocytes from ana-
lysis. Cells were analyzed and sorted on a BD FACS-Aria
II containing 355 nm UV, 488 nm blue, 561 nm yellow-
green and 633 nm red lasers. An overview of the FACS
proportions of the individual animals used for this study
can be found in Additional file 2.
Generation of cDNA by direct reverse transcription &
qPCR analysis
For analysis of transcript levels by qPCR, cells were
sorted directly into lysis buffer (10 IU RNase inhibitor
(Invitrogen), 2 mM DTT, 0.15% Tween-20 (Biorad) in
10 μL of nuclease-free water) in PCR tubes. 500 cells
were sorted into each tube, making approximately 12 μL
total volume. Reverse transcription was performed using
Superscript VILO (Invitrogen #11754) as per manufac-
turers protocol. Primers were designed that span introns
to exclude the detection of genomic DNA and selected
for optimum melt curve and amplification profiles (for
primer sequences, see Additional file 9). qPCR was per-
formed using SSo Fast Evagreen supermix reagent
(Biorad #172-500) as per manufacturers protocol. Per
condition 3 animals were assayed, normalized by HPRT
(validated to be consistent between groups), averaged
and compared to Virgin samples according to the
delta-delta c (t) method. The relative values from 3-5
sets of mice were assessed by paired t-test for statistical
significance.
Preparation of RNA for the microarray
For Microarray analyses, cells were sorted directly into
lysis buffer (20 IU RNase inhibitor (Invitrogen), 2 mM
DTT, 0.15% Tween-20 (Biorad) in 8 μL of nuclease-free
water) in PCR tubes. 1000 cells were sorted into each
tube, making approximately 12 μL total volume. The
cells were allowed to lyse for 15 minutes on ice and
stored at -80 degrees. RNA from 2 μL of lysed cells
(equivalent of 167 cells) was amplified and labelled with
Biotin using the TargetAmp™ 2-Round Biotin-aRNA
Amplification Kit 3.0 (epicentre #TAB2R710) as per themanufacturers protocol. Sorting a thousand cells improves
the representation of the HR+ population and the accur-
acy of the sort (because of the collection volume of 8 μL).
The maximum input in the TargetAmp Kit was 2 μL and
we used the leftover RNA for quality controls. The Targe-
tAmp output was subjected to SuperScript® II Reverse
Transcriptase (Invitrogen #18064) and SuperScript® III
Reverse Transcriptase (Invitrogen #180800) to synthesize
cDNA and RNA Clean & Concentrator™(ZYMO Research
#R1017) and RNeasy MinElute Cleanup Kit (Qiagen
#74204) were used to purify the RNA as recommended by
the amplification protocol. The concentration and pur-
ity of the Biotin-labelled aRNA was determined by
using a NanoDrop spectrophotometer (Thermo Scientific-
NanoDrop 2000).
Microarray analysis
Microarray hybridization and scanning was performed by
the Genomic and RNA Profiling Core Facility at DUKE-
NUS Graduate Medical School. 1.5 μg of biotinylated a/
cRNA from each sample was hybridized at 58°C for
16 hours using the Illumina Whole-Genome Gene Expres-
sion Direct Hybridization Assay system with the Illumina
Mouse WG-6 v2.0 (six-sample BeadChip) platform. The
signal was developed using streptavidin-Cy3 and the
BeadChips were scanned with an Illumina BeadArray
Reader. Raw signals were logarithmically transformed (to
base 2) and quantile normalized. The background noise
from the array was determined at 100, and probes with an
average signal <100 in all comparator groups were re-
moved from further analysis (this reduced the number of
analyzed probes from 45281 to 19821). Differential gene
expression between pregnant and virgin samples was
expressed as a log ratio of the average logged signals
between the compared groups. Statistical significance of
differential gene expression was assessed by a regularized
t-test adapted for small replication groups (Cyber-T, [55]).
False discovery rates (FDR) were generated on the nominal
p-values by the multiple testing correction procedure of
Benjamini and Hochberg [56]. Generally, genes with an
absolute fold-change of 2-fold or higher and a FDR less
than or equal to 10% were considered to be significantly
and differentially expressed and formed the basis for com-
paring gene lists from each comparison (3D vs Vir and 7D
vs Vir). For each probe, a combined metric (Pi score)
based on the signed log ratio and the FDR was additionally
defined [57] and computed as follows: Pi = (log ratio)*
(-log10 [FDR]). The Pi score was used to determine the
top 25 up- and down-regulated genes in the 3-day and
7-day pregnant samples compared to the virgin group.
Principal components analysis was conducted on the ex-
pression covariance matrix to identify potential sample
outliers (Partek Genomics Suite, version 6.6). The micro-
array data from this publication have been submitted to
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GSE63720.
Pathway enrichment analysis
Pathway enrichment analysis was conducted via the over-
representation analysis (ORA) method in the Ingenuity
Pathway Analysis (IPA) tool (Ingenuity Systems, www.
ingenuity.com). A pre-filtered list of differentially ex-
pressed genes (absolute fold-change ≥ 2-fold and FDR ≤
10%) were used as input for each comparison. Pathway en-
richment was assessed on the list of canonical pathways
from the Ingenuity Knowledge Base. Over-representation
of biological pathways was ascertained via Fisher’s exact
test and corrected for multiple testing by the Benjamini-
Hochberg procedure.
Declaration of compliance with guidelines for the use of
animals in this study
All procedures were performed in accordance with the
guidelines for ethical treatment of laboratory animals ap-
proved by the SingHealth Institute Animal Care and Use
Committee, Singapore. FVB/N mice were purchased from
Jackson Laboratory and bred and maintained in the ani-
mal facility of the DUKE-NUS Graduate Medical School
and The National Cancer Centre, Singapore under guide-
lines for housing and husbandry conditions of each insti-
tute. Mice were euthanized by carbon dioxide inhalation
and cervical dislocation. Effort was taken to ensure good
animal welfare and prevent suffering.
Availability of supporting data
The data set supporting the results from this article is avail-
able in the NCBI Gene Expression Omnibus, GSE63720.
Additional files
Additional file 1: Gating strategy used for fluorescence-activated
cell sorting (FACS). Cell doublets and debris were excluded from the
murine mammary gland cell suspension using the Forward and Side scatter
parameters. Single viable cells were gated using DAPI before excluding
lymphocytes using CD45. CD24 and CD49f were used to subdivide the
epithelial cells into Luminal and Basel lineages. The luminal population was
further subdivided into the HR+ and Alveolar cell populations using Sca1
and CD49b expression.
Additional file 2: FACS proportions of mammary epithelial
subpopulations of the samples used for the microarray. (A) Proportion
of basal (blue) and luminal (green) epithelial cells based on FACS using
cell surface markers CD24 and CD49f for cells isolated from 3 virgin mice
(Vir-1, Vir-2 and Vir-3), 3 mice that were 3-days pregnant (3D-1, 3D-2 and
3D-3) and 3 mice that were 7 days pregnant (7D-1, 7D-2 and 7D-3).
(B) Proportion of hormone receptor positive (HR+, purple) and alveolar
progenitor (yellow) luminal cells based on FACS using cell surface
markers Sca1 and CD49b for the same samples shown in (A).
Additional file 3: Immuno-fluorescence staining illustrating the
reduction of hormone receptor expression during pregnancy.
Estrogen Receptor (ER, green), Progesterone Receptor (PR, red), Cyto-keratin 8
(CK8, blue) and DAPI (Grey). Scale bar, 10 μm. Images were acquired with a
fixed exposure time.Additional file 4: List of genes that significantly change in hormone-
sensing cells at day 3 and day 7 of pregnancy. (A) List of 165 genes
differentially expressed in HR+ cells at day 3 of pregnancy compared to virgin
animals based on Venn analysis conducted on a list of genes that had an
absolute fold-change of > = 2-fold and a FDR of 10% or less. Since some
genes are represented by multiple Illumina probes, the analysis was
conducted at the gene symbol level. (B) List of 401 genes differentially
expressed in HR+ cells at both day 3 and 7 of pregnancy compared to virgin
animals based on Venn analysis. (C) List of 605 genes differentially expressed
in HR+ cells at day 7 of pregnancy compared to virgin animals based on Venn
analysis.
Additional file 5: Enrichment for gene function by Ingenuity
Pathway Analysis (IPA) systems. List of genes belonging to canonical
Ingenuity pathways that were differentially expressed in HR+ cells in
early pregnancy. Pathway enrichment analysis was conducted via
over-representation analysis in Ingenuity Pathway Analysis software,
using a pre-filtered list of differentially expressed genes (absolute fold-
change ≥ 2-fold and FDR ≤ 10%) as the input. Pathway significance was
ascertained by the right-tailed Fisher’s exact test (column B) and the ratio
of the number of pathway-specific differentially expressed genes to the
total number of genes for the pathway are shown in column C. Columns
D-O list the individual differentially expressed genes for each pathway.
Additional file 6: Cell cycle regulators identified in HR+ cells in
early pregnancy. (A) Fold change of Log 2 expression of pre-selected
cell cycle genes at pregnancy day 3 and 7 compared to virgin samples.
At 3 days of pregnancy, up-regulated genes are indicated in red, down-
regulated genes in green and unchanged genes in grey. (B) Schematic
representation of pre-selected genes involved in cell cycle regulation
at 3 days of pregnancy. Up-regulated genes are indicated in red,
down-regulated genes in green and unchanged genes in grey.
Additional file 7: List of genes encoding secreted factors that are
differentially expressed in HR+ cells at day 7 of pregnancy. (A) List
of genes encoding secreted factors differentially expressed at day 7 of
pregnancy compared to virgin animals. Data was generated by cross-
comparing the genes of interest against the master list of Uniprot
proteins with subcellular location = ‘secreted’ (confidence level = any).
This list corresponds to the Gene Ontology term “extracellular region
(GO0005576)”. (B) Top 50 up-regulated genes encoding secreted factors
at day 7 of pregnancy. (C) Top 50 down-regulated genes encoding
secreted factors at day 7 of pregnancy.
Additional file 8: Antibodies used in confocal immunofluorescence
and fluorescence-activated cell sorting (FACS).
Additional file 9: Nucleic acid sequences for primers used in
Quantitative polymerase chain reaction (qPCR) experiments.Abbreviations
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